Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.
We are building a world-class gene therapy company. Our proprietary rational design platform enables us to methodically engineer the next generation of AAV vectors and gene therapies. We’re finding solutions to the greatest challenges the field is facing, from tissue selectivity and immunogenicity to manufacturing yields, and payload capacity. We have an experienced team that is focused on discovering, developing, and manufacturing breakthrough medicines to transform people’s lives.
Total Funding: $170 M
Funding Stage: Series B
Business Stage: Scaling Up
Market: B2B
Company Size: 51 to 100
Founded: 2019
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Affinia Therapeutics
Vice President Finance, Controller
Waltham, Massachusetts
Senior Research Associate, Analytical Sciences - Manufacturing
Waltham, Massachusetts
Medical Director, Clinical Development
Waltham, Massachusetts
Senior Research Associate, Analytical Sciences
Waltham, Massachusetts
Research Associate/ Snr. RA- In Vivo Technician
Waltham, Massachusetts
